



Effective Health Care Weight Loss Interventions and Chronic Kidney Disease Nomination Summary Document

Results of Topic Selection Process & Next Steps

- Ongoing research or activities are underway that impact the timing for developing this topic. Therefore, weight loss interventions and chronic kidney disease will be revisited in the future when more data becomes available.

Topic Description

Nominator: Organization

Nomination Summary: The nominator is interested in the comparative effectiveness of weight loss interventions in preventing chronic kidney disease (CKD) or slowing CKD progression.

Staff-Generated PICO

Population(s): Patients with or at risk for CKD, including adults, children, elderly, obese, African Americans, disparity populations

Intervention(s): Weight loss interventions

Comparator(s): No therapy or intervention; other weight loss interventions

Outcome(s): Estimated glomerular filtration rate (eGFR), creatinine, albuminuria, incidence of end stage renal disease (ESRD), other measurements of disease status and progression

Key Questions from Nominator:

1. What is the comparative effectiveness of overweight prevention, weight maintenance and weight loss interventions in preventing chronic kidney disease (CKD) or slowing CKD progression?

Considerations

- The topic meets all EHC Program selection criteria. (For more information, see <http://effectivehealthcare.ahrq.gov/index.cfm/submit-a-suggestion-for-research/how-are-research-topics-chosen/>.)
- Chronic kidney disease is a significant public health problem and identifying strategies to improve the care and clinical outcomes of patients with CKD is of high public health interest. It is currently unknown which weight loss strategy (e.g., pharmacological, lifestyle, or surgical) is most effective at improving CKD outcomes. Ongoing trials are assessing the comparative effectiveness of weight loss interventions in slowing CKD progression and long-term clinical outcomes in participants; this topic will be reconsidered when this additional trial data is available.